ESR1 and breast carcinoma: Moreover, we confirmed that alpelisib alone and in combinations is more selective for ERα + breast cancer cells and those with PI3Kα mutation(s) rather than ERα- ones and those with wild-type PI3Kα (Fig. S7B and Fig. 3D–J).